Clinical Trial Detail

NCT ID NCT00812240
Title A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AB Science
Indications

gastrointestinal stromal tumor

Therapies

Masitinib

Imatinib

Age Groups: adult

Additional content available in CKB BOOST